You are currently browsing the Piercing and Tattoo News weblog archives for March, 2007.

Stark unveils health bill ‘AmeriCare’

WASHINGTON, March 29 (UPI) — U.S. House Ways and Means Health Subcommittee Chairman Pete Stark, D-Calif., this week introduced a universal health coverage bill.
“Employers, unions, consumer groups and presidential candidates are all debating not whether our health care system needs reform, but how it should be improved,” Stark said.
Under Stark's plan, called AmeriCare, […]

MS patients seek more practical support

LONDON, March 30 (UPI) — A study by researchers at King's College London found patients with multiple sclerosis are lacking practical, everyday help beyond medical treatments.
In the study of 445 British patients with different levels of multiple sclerosis, 29 percent said medical treatment was their top priority when it came to meeting their […]

Neopharm’s colon-cancer drug falls short

WAUKEGAN, Ill., March 30 (UPI) — Neopharm's experimental treatment for metastatic colorectal cancer, LE-SN38, missed its mark in a Phase 2 study, the company said late Friday. Neopharm had been testing the drug as a second-line therapy for metastatic colorectal cancer.
The drug maker said an interim analysis of data following treatment of the first […]

Analysis: Report blasts AIDS funding rules

By OLGA PIERCE UPI Health Business Correspondent
WASHINGTON, March 30 (UPI) — The $15 billion fund that is the major source of U.S. global AIDS giving should abandon its system of earmarking funding — especially for abstinence-based programs — according to a new report from the Institutes of Medicine.
“We are recommending Congress to remove budget […]

Analysis: Surge forecast for Pharmion drug

By STEVE MITCHELL UPI Senior Medical Correspondent
WASHINGTON, March 30 (UPI) — Pharmion's Thalidomide may see a surge in front-line use in multiple myeloma after its expected approval in Europe, according to an analyst report.
Friedman, Billings and Ramsey surveyed physicians and found that, although only about 8 percent presently use the drug off-label for […]